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This bulletin provides an analysis of data collected in the first drug prevalence survey of households in Ireland and Northern 
Ireland on the use of Sedatives, Tranquillisers or Anti-depressants. The survey sampled a representative number of people 
aged between 15 and 64 during late 2002 and early 2003. This bulletin contains data on lifetime (ever used), last year 
(recent use) and last month (current use). It also investigates age of first use, frequency of use, method of taking sedatives, 
tranquillisers or anti-depressants, how they were obtained and presents a profile of users in this study.
IRELAND – Key Findings
■ Prevalence rates were higher among 
older respondents – the lifetime 
prevalence rate for those aged 35 to  
64 (16%) was double that of those 
aged 15 to 34 (8%).
■ Female respondents reported higher 
prevalence rates than males across  
all time periods.
■ The average age respondents  
reported they had first used sedatives, 
tranquillisers or anti-depressants was  
28 years for males and 30 for females.
■ The majority of current users (81%) took 
sedatives, tranquillisers or anti-
depressants daily or almost daily.
■ Almost all current users (98%)  
took sedatives, tranquillisers or  
anti-depressants in tablet form.
■ Most current users (95%) got  
their sedatives, tranquillisers or  
anti-depressants on prescription.
■ Respondents who were separated, 
divorced or widowed reported higher 
prevalence rates than those who were 
single (never married), co-habiting or 
married.
■ Associations were found between  
various indicators of deprivation and 
higher prevalence rates. These indicators 
included: being dependent on the state 
long term, not being in paid work, lower 
levels of educational attainment, leaving 
education before 15 years of age and 
living in local authority/housing 
association homes.
NORTHERN IRELAND –  
Key Findings
■ Prevalence rates were higher among 
older respondents – the lifetime 
prevalence rate for those aged 35  
to 64 was 27%, compared to 16%  
for respondents aged 15 to 34.
■ Female respondents reported higher 
prevalence rates than males across  
all time periods.
■ The average age that respondents 
reported they had first used sedatives, 
tranquillisers or anti-depressants was  
32 years for males and 30 for females.
■ The majority (84%) of current  
users took sedatives, tranquillisers or 
anti-depressants daily or almost daily.
■ Almost all current users (99%) took 
sedatives, tranquillisers or  
anti-depressants in tablet form.
■ Most current users (98%) got  
their sedatives, tranquillisers or  
anti-depressants on prescription.
■ Respondents who were separated, 
divorced or widowed reported higher 
prevalence rates than those who were 
single (never married), co-habiting or 
married.
■ Associations were found between  
various indicators of deprivation and 
higher prevalence rates. These indicators 
included: being dependent on the state 
long term, not being in paid work, having 
no educational qualifications and living in 
Housing Executive/housing association 
homes.
IRELAND AND NORTHERN 
IRELAND COMPARISON –  
Key Findings
■ In all instances, use of sedatives, 
tranquillisers or anti-depressants  
was higher in Northern Ireland than  
in Ireland.
■ Females reported higher prevalence  
rates than males in both jurisdictions.
■ Prevalence rates were higher amongst 
older respondents in both Ireland and 
Northern Ireland.
■ Throughout the island of Ireland the 
pattern of obtaining sedatives, 
tranquillisers or anti-depressants was  
the same – nearly all users took tablets 
that they had obtained on prescription.
■ Across the whole island of Ireland 
respondents who were separated, 
divorced or widowed reported higher 
prevalence rates than those who were 
single (never married), co-habiting or 
married.
■ Associations were found between  
various indicators of deprivation and 
higher prevalence rates (lower socio-
economic groups, not being in paid 
work, lower educational attainment  
and living in public housing). The  
pattern was the same in both Ireland 
and Northern Ireland.
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Introduction
The 2002/2003 Drug Prevalence Survey was commissioned  
by the National Advisory Committee on Drugs (NACD) in  
Ireland and the Drug and Alcohol Information and Research  
Unit (DAIRU) within the Department of Health, Social Services 
and Public Safety (DHSSPS) in Northern Ireland.
The main focus of the survey was to obtain prevalence rates  
for key illegal drugs, such as cannabis, ecstasy, cocaine, and 
heroin, on a lifetime (ever used), last year (recent use), and  
last month (current use) basis. Similar prevalence questions 
were also asked of alcohol, tobacco, and other drugs  
(e.g. tranquillisers); attitudinal and demographic information  
was also sought from respondents.
Following open tender, the contract for conducting the survey 
was awarded to MORI MRC.
Methodology
The questionnaire and methodology for this survey were  
based on best practice guidelines drawn up by the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA).  
The questionnaires were administered through face-to-face 
interviews with respondents aged between 15 and 64 years and 
who are normally resident in households in Ireland and Northern 
Ireland. Thus persons outside these age ranges, or who do not 
normally live in private households, have not been included in 
the survey. This approach is commonly used throughout the EU 
and because of the exclusion of those living in institutions (for 
example prisons, nursing homes etc.) this type of prevalence 
survey is usually known as a general population survey.
Fieldwork for the survey was carried out between October  
2002 and April 2003 and the final achieved sample comprised 
of 8,434 respondents (4,918 in Ireland and 3,516 in Northern 
Ireland). The response rate for the survey was 70% in Ireland 
and 63% in Northern Ireland.
The sample was weighted by gender, age, Health Board1 in 
Ireland and Health and Social Services Board area in Northern 
Ireland, to maximise its representativeness of the general population.
Details of the methodology have been summarised in a paper 
published on the websites of the NACD (http://www.nacd.ie/) and 
the DHSSPS (http://www.dhsspsni.gov.uk/) and a comprehensive 
technical report containing copies of the questionnaires used  
in both jurisdictions is published on both websites.
Confidence intervals for all prevalence data contained in Bulletins 
1 and 2 are published on the websites above.
Previous Publications
Initial results from the 2002/2003 Drug Prevalence Survey were 
published in Bulletin 1 (October 2003, revised June 2005), 
which gave lifetime, last year, and last month prevalence rates for 
key drugs for the island of Ireland, Ireland and Northern Ireland.
Bulletin 2, published in March 2004 (revised June 2005), 
contained comparable information for Ireland and its constituent 
Health Boards and Northern Ireland and its constituent Health 
and Social Services Board areas. Prevalence rates for alcohol  
and tobacco (and, relating to Northern Ireland only, for anabolic 
steroids and Nubain®) were also included in the tables.
1 Since January 2005 the Health Boards in Ireland have undergone restructuring and are merged under one authority – the Health Service Executive.  
The above reference relates to the Health Board structure detailed in Bulletin 2 – Drug Use in Ireland and Northern Ireland 2002/2003 Drug Prevalence  
Survey: Health Board (Ireland) & Health and Social Services Board (Northern Ireland) Results (Revised).
What is Prevalence?
The term prevalence refers to the proportion of a 
population who have used a drug over a particular 
time period. In general population surveys, prevalence 
is measured by asking respondents in a representative 
sample drawn from the population to recall their 
use of drugs. The three most widely used recall 
periods are: lifetime (ever used a drug), last year 
(used a drug in the last twelve months), and last 
month (used a drug in the last 30 days). Provided 
that a sample is representative of the total population, 
prevalence information obtained from a sample can 
be used to infer prevalence in the population.
Lifetime prevalence refers to the proportion of the 
sample that reported ever having used the named 
drug at the time they were surveyed. A person who 
records lifetime prevalence may or may not be 
currently using the drug. Lifetime prevalence should 
not be interpreted as meaning that people have 
necessarily used a drug over a long period of time 
or that they will use the drug in future.
Last year prevalence refers to the proportion of  
the sample that reported using a named drug in  
the year prior to the survey. For this reason, last  
year prevalence is often referred to as recent use.
Last month prevalence refers to the proportion  
of the sample that reported using a named drug  
in the 30 day period prior to the survey. Last month 
prevalence is often referred to as current use.  
A proportion of those reporting current use may  
be occasional (or first-time) users who happen to 
have used in the period leading up to the survey – 
it should therefore be appreciated that current use 
is not synonymous with regular use.
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Bulletin 3 (2002/2003 Drug Prevalence Survey: Cannabis 
Results) published in October 2005, examined age of first use, 
regular use, type of cannabis used, method by which cannabis is 
used, how and where cannabis is obtained, reasons for stopping 
use, attitudes to cannabis use and perceptions of risk, together 
with the typical profile of cannabis users.
Bulletin 4 (2002/2003 Drug Prevalence Survey: Cocaine Results) 
published in January 2006, contained prevalence rates for the 
use of cocaine and other information relating to cocaine use in 
Ireland and Northern Ireland including – age of first use; regular 
use, type of cocaine used (powder or crack), method by which 
cocaine is consumed, how and where cocaine is obtained, reasons 
for stopping use, perceptions of risk and a typical profile of users.
Bulletin 5 (2002/2003 Drug Prevalence Survey: Polydrug Use 
Results) published in December 2006, contained findings on 
polydrug use (the use of more than one substance within a 
specific time preiod). Analysis was carried out on data collected 
for last month use for both legal and illegal drugs. A comparison 
of findings between Ireland and Northern Ireland was also made.
Understanding the Results of this Bulletin
This bulletin contains prevalence rates for the use of sedatives, 
tranquillisers or anti-depressants and other information relating  
to use of sedatives, tranquillisers or anti-depressants in Ireland 
and Northern Ireland. Results are given for all respondents aged 
between 15 and 64, by gender and by age group (15 to 34  
and 35 to 64).
Respondents were asked about these drugs as a collective,  
i.e. did you ever use sedatives, tranquillisers or anti-depressants? 
A list of examples was provided to the interviewees and they 
were invited to reply “yes” or “no”. They were not asked to state 
which drug they had used as all three were grouped together. 
The list was not intended to be exhaustive and only acted as  
a prompt for the interviewees presenting a list of some names  
of sedatives, tranquillisers or anti-depressants. The data cannot 
therefore be broken down by drug group and cannot be 
interpreted to reflect any single drug group, but only the 
collective as asked “sedatives, tranquillisers or anti-depressants”.
Readers should note that the total sample size for each group  
is given at the head of each column. As in all sample surveys, 
the greater the sample size the more statistically reliable the 
results become.
Invalid responses have been excluded from all analyses. 
Percentages may not always sum to 100 due to either the  
effect of rounding or where respondents could give more than 
one answer.
Statistical significance tests (Chi-Square Tests) have been carried 
out on a range of variables. These tests are used to establish the 
degree of confidence with which we can infer that the observed 
findings are an accurate reflection of the views of the population. 
In this bulletin, where test results have emerged as statistically 
significant, this has been reported at the 5% level of probability 
(p ≤ 0.05). Therefore, where a value of p less than or equal to 
0.05 was found, we can be confident that 95 times out of 100 
the outcomes that we have observed are real, i.e. not due to 
sampling error.
In an attempt to compare prevalence rates for drug use across 
different social classes/socio-economic groups, the Standard 
Occupational Classification (SOC2000) was used. The SOC2000 
is based on the employment status, level of responsibility and 
qualifications, of the chief income earner within a household. 
Further information is available in the technical report on the 
NACD website (http://www.nacd.ie/publications/prevalence_
allireland.html)
Respondents were then coded into the following social grades:
A (Professionals, senior management and top civil servants)
B (Middle management, senior civil servants, managers  
and owners of businesses)
C1 (Junior management and owners of small businesses)
C2 (Skilled manual workers and manual workers responsible 
for other workers)
D (Semi-skilled and unskilled manual workers, trainees  
and apprentices)
E (All those dependant on the State long-term)
Glossary
Sedatives and tranquillisers 
Sedatives and tranquillisers are commonly used terms  
for the same group of medicines which depress, slow 
down or calm the brain and central nervous system.  
They are mainly Benzodiazepines (“Benzos”) but other 
drugs with the same effects, e.g. Zolpidem and Zopiclone 
are included in this group. Medically they are often 
referred to as Hypnotics, which induce sleep and 
Anxiolytics or anti-anxiety agents.
The same drug can be used as a hypnotic or as an  
anti-anxiety agent depending on the dose used and  
on the time of day that they are used. Hypnotics are  
used to treat insomnia (lack of adequate restful sleep) 
which is causing distress. Anxiolytics are also referred to  
as “minor tranquillisers”. Benzodiazepine anxiolytics are  
the most common type used to obtain relief of severe  
and disabling anxiety.
Anti-depressants 
These are medicines used to treat conditions such  
as the low or sad mood, loss of interest or pleasure  
in daily activities, fatigue & energy loss usually known  
as Depression. Different drug classes are available on 
prescription to treat Depression.
All of these drugs above are prescribed under medical 
supervision and can only be obtained by prescription  
from a pharmacist.
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Results – Ireland
Prevalence of sedatives, tranquillisers  
or anti-depressants (Table 1)
Almost one-in-eight respondents (12%) aged 15 to 64 reported 
that they had taken sedatives, tranquillisers or anti-depressants  
at some stage in their lives, with 6% having used in the last year 
and 4% having used in the last month.
Age (Table 1)
Overall, prevalence rates were lower among younger 
respondents, with older age groups reporting higher prevalence 
rates. The lifetime prevalence rate for those aged 35 to 64 
(16%) was nearly double that for those aged 15 to 34 (8%).
Gender (Table 1)
Female respondents reported higher prevalence rates than males 
across all time periods. The lifetime prevalence figure for females 
was 15% compared to 9% for males. Similarly, the figures for last 
year use were 7% for females and 4% for males, whilst the last 
month prevalence rate for females was 5% and 3% for males.
First use (Table 2)
The average2 age that respondents reported they had first  
used sedatives, tranquillisers or anti-depressants was 30 years. 
The figure was 28 years for males and 30 for females. Younger 
respondents (aged 15 to 34) reported first using sedatives, 
tranquillisers or anti-depressants at 20 years. Older respondents 
(aged 35 to 64) reported an average age of first use of 35 
years.
Frequency of use (Table 3)
More than four-in-five (81%) current users use sedatives, 
tranquillisers or anti-depressants on a daily or almost daily basis,  
3% use them several times a week, 4% used them at least once  
a week and 10% use them less than once a week.
The frequency with which males and females used sedatives, 
tranquillisers or anti-depressants did not differ greatly. Over four- 
in-five (81%) of both males and females used them on a daily  
or almost daily basis.
A greater proportion of young adults (23%) reported using 
sedatives, tranquillisers or anti-depressants less than once per week 
than did older adults (5%)
Method of taking sedatives, tranquillisers  
or anti-depressants3 (Table 4)
The majority of current users (98%) take tablets. Only 2%  
inject sedatives, tranquillisers or anti-depressants. Just 1% 
reported using some other method. More males (5%) than 
females (1%) reported injecting/using a needle.
How sedatives, tranquillisers  
or anti-depressants were obtained (Table 5)
All current users of sedatives, tranquillisers or anti-depressants 
were asked how they had obtained their drugs. Nearly all 
respondents (95%) had got them on prescription. Only 2%  
of respondents had got them from someone else they knew. 
Just 1% had bought them without a prescription in a chemist.
Nearly all (98%) older respondents (those aged 35-64) who 
were currently using sedatives, tranquillisers or anti-depressants 
had obtained them on prescription. The corresponding figure  
for those aged 15-34 was 84%. Moreover, 8% of younger 
respondents had obtained them from someone else they  
knew. Only 0.5% of older respondents had obtained sedatives, 
tranquillisers or anti-depressants in this way.
User profile – sedatives, tranquillisers  
or anti-depressants
Gender (Table 6)
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
gender and use of sedatives, tranquillisers or anti-depressants. 
Females are more likely than males to have ever used sedatives, 
tranquillisers or anti-depressants, to have used them in the last 
twelve months and to have used them in the last month.
2 The median was used to measure central tendency in the case of age of first use to avoid extreme values skewing the results.
3 This was a multi-choice question and therefore percentages will not equal 100%.
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Age (Table 7)
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
age and use of sedatives, tranquillisers or anti-depressants. Older 
respondents reported higher prevalence rates than expected 
across all three prevalence categories.
Socio-economic group (SEG) (Table 8)
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
SEG and use of sedatives, tranquillisers or anti-depressants  
on a lifetime, last year or last month basis. Respondents from 
SEG category E (all those dependant on the State long term) 
reported higher levels of use.
Work status (Table 9)
The results of the three chi-square tests were statistically 
significant. This indicates that there is an association between 
work status and use of sedatives, tranquillisers or anti-
depressants. Respondents who reported they were not in paid 
work had higher than expected prevalence rates across all three 
time periods. This was also the case for respondents who 
reported their work status as something other than “in paid 
work”, “not in paid work”, or “student”.
Housing tenure (Table 10)
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
housing tenure and use of sedatives, tranquillisers or anti-
depressants. Respondents who rented their houses from a  
local authority or housing association reported higher levels  
of use on a lifetime, last year and last month basis.
Age education ceased (Table 11)
A general trend was observed where those respondents who 
had ceased education aged 15 years or under reported higher 
levels of use of sedatives, tranquillisers or anti-depressants. 
However, this association was only statistically significant for the 
data relating to use within the last year. It was not statistically 
significant for the lifetime or last month prevalence data.
Education Level (Table 12)
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
education level and use of sedatives, tranquillisers or anti-
depressants. Respondents who had obtained an elementary 
school only level of education reported higher prevalence  
rates of use on a lifetime, last year and last month basis.
Marital Status (Table 13)
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association  
between marital status and use of sedatives, tranquillisers  
or anti-depressants. Respondents who were separated,  
divorced or widowed reported higher prevalence rates  
over the three time periods.
4 See classification of Socio-Economic Groups on page 4.
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Results – Northern Ireland
Prevalence of sedatives, tranquillisers  
or anti-depressants (Table 14)
Over one-in-five respondents (22%) aged 15 to 64 reported that 
they had taken sedatives, tranquillisers or anti-depressants at some 
stage in their lives, with 13% having used in the last year and 
10% having used in the last month.
Age (Table 14)
Prevalence rates were lower among young respondents, and 
higher within older age groups. The lifetime prevalence rate  
for those aged 35 to 64 was 27%. The corresponding figure  
for those aged 15 to 34 was 16%.
Gender (Table 14)
Female respondents consistently reported higher prevalence 
rates than males. The lifetime prevalence figure for females was 
29% compared to 16% for males. Similarly, the figures for last 
year use were 17% for females and 9% for males. The last 
month prevalence rate for females was 13% and 7% for males.
First use (Table 15)
The average5 age that respondents reported they had first  
used sedatives, tranquillisers or anti-depressants was 30  
years. Males reported an average age of first use of 32 years. 
Females reported first using at the younger age of 30 years.
Younger respondents (aged 15 to 34) reported first using 
sedatives, tranquillisers or anti-depressants at 22 years. Older 
respondents (aged 35 to 64) reported an average age of first 
use of 37 years.
Frequency of use (Table 16)
More than four-in-five (84%) current users use sedatives, 
tranquillisers or anti-depressants on a daily or almost daily basis,  
4% used them several times a week, 5% used them at least  
once a week and 6% used them less than once a week.
There was very little difference in the frequency of use between 
younger (15-34) and older (35-64) respondents.
The frequency with which males and females used sedatives, 
tranquillisers or anti-depressants did not differ greatly. Over four  
in five (82%) males (compared with 85% of females) used  
them on a daily or almost daily basis. A slightly larger proportion  
of males (8%) than females (5%) reported using them less than 
once a week.
Method of taking sedatives, tranquillisers  
or anti-depressants (Table 17)
The majority of current users (99%) take sedatives,  
tranquillisers or anti-depressants in tablet form. Only 2% 
reported injecting/using a needle and just 1% reported  
using some other method. A larger proportion of younger 
respondents (5%) reported injecting sedatives, tranquillisers  
or anti-depressants. Only 1% of older adults reported using  
this method.
How sedatives, tranquillisers or  
anti-depressants were obtained (Table 18)
Nearly every current user of sedatives, tranquillisers or  
anti-depressants (98%) had got them on prescription. This  
trend was apparent across gender and all age groups. Only  
1% had bought them without a prescription in a chemist.  
Less than one per cent (0.3%) of respondents had got  
them from someone else they knew.
User profile – sedatives, tranquillisers  
or anti-depressants
Gender (Table 19)
The results of all three chi-square tests were statistically significant. 
This indicates that there is an association between gender and 
use of sedatives, tranquillisers or anti-depressants. Females are 
more likely than males to have ever used sedatives, tranquillisers 
or anti-depressants, used them in the last year and used them  
in the last month.
Age (Table 20)
The results of the three chi-square tests were statistically 
significant. This indicates that there is an association between  
age and use of sedatives, tranquillisers or anti-depressants.  
Older respondents reported higher prevalence rates across  
the three time periods.
5 The median was used to measure central tendency in the case of age of first use to avoid extreme values skewing the results.
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Socio-economic group (SEG) (Table 21)
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
SEG and use of sedatives, tranquillisers or anti-depressants  
on a lifetime, last year or last month basis. Respondents  
from SEG category E (all those dependant on the State  
long term) reported higher prevalence rates in all three  
time periods.
Work status (Table 22)
The results of the three chi-square tests were statistically 
significant. This indicates that there is an association  
between work status and use of sedatives, tranquillisers  
or anti-depressants. Respondents who were not in paid  
work had higher than expected prevalence rates for lifetime,  
last year and last month use of sedatives, tranquillisers  
or anti-depressants. Students reported very low prevalence  
rates in all three prevalence categories.
Housing tenure (Table 23)
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association  
between housing tenure and use of sedatives, tranquillisers  
or anti-depressants. Respondents who rented their houses from  
the Housing Executive or a local housing association reported 
higher prevalence rates for lifetime, last year and last month basis.
Educational qualifications (Table 24)
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
educational qualifications and use of sedatives, tranquillisers or 
anti-depressants. Respondents with no qualifications reported 
higher lifetime, last year and last month prevalence rates.
Marital Status (Table 25)
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association  
between marital status and use of sedatives, tranquillisers  
or anti-depressants. Respondents who were separated,  
divorced or widowed reported higher prevalence rates  
over the three time periods.
6 See classification of Socio-Economic Groups on page 4.
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Comparison – Ireland  
and Northern Ireland
Prevalence
In all instances, use of sedatives, tranquillisers or anti-depressants 
was higher in Northern Ireland than in Ireland. The figure for 
lifetime use in Northern Ireland (22%) was nearly double that 
reported for Ireland (12%). The figures for recent use were 
similarly proportioned. The last year prevalence rate was 13%  
in Northern Ireland and 6% in Ireland. Likewise, the figure for 
current use was higher in Northern Ireland (10%) than it was  
in Ireland (4%).
Obtaining sedatives, tranquillisers  
or anti-depressants
Throughout the island of Ireland the pattern was the same – 
nearly all users took tablets that they had obtained on 
prescription.
Profile of users
The profile of those who used sedatives, tranquillisers or  
anti-depressants was similar throughout the island of Ireland.
Females and older respondents reported higher prevalence  
rates. These associations were found to be statistically significant 
in both jurisdictions.
There were also statistically significant associations between 
marital status and use in both Ireland and Northern Ireland. 
Respondents who were separated, divorced or widowed were 
more likely than respondents who were single (never married), 
cohabiting or married to use sedatives, tranquillisers or anti-
depressants.
Significant associations were also found between social class  
and the use of sedatives, tranquillisers or anti-depressants.  
Those respondents who were dependent upon the State  
long term in both Ireland and Northern Ireland reported higher 
prevalence rates. Similarly, associations between working status  
and use of these drugs were also noted. Those who were not  
in paid work in both Ireland and Northern Ireland reported  
higher prevalence rates.
Further associations were found between educational  
level attained in Ireland (lower levels of attainment such as 
“primary/elementary school only” were associated with higher 
levels of use) and educational qualification in Northern Ireland 
(those with no qualifications reported higher prevalence rates). 
Significant associations were also found between age education 
ceased and use of sedatives, tranquillisers and anti-depressants 
in Ireland on a last year and last month basis. More respondents  
who left school before 15 years-of-age reported using sedatives, 
tranquillisers or anti-depressants.
In addition to these trends associations between housing tenure 
and use of sedatives, tranquillisers or anti-depressants were 
evident in both jurisdictions. In Ireland people who rented their 
houses from a local authority or housing association reported 
higher levels of use. A similar trend was noted in Northern 
Ireland. Those respondents who rented their homes from the 
Housing Executive or a local housing association used sedatives, 
tranquillisers or anti-depressants more than those who owned 
their home or rented privately.
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Table 1: Ireland
Sedatives, Tranquillisers or Anti-depressants – Prevalence Rates (%)
 All    Young  Older 
 adults   adults  adults  
 15-64 Males Females 15-34 35-64
Total Weighted N (valid responses) (4918) (2470) (2448) (2333) (2585)
Lifetime Prevalence (%) 12.1 9.3 15.0 8.2 15.7
Last Year Prevalence (Recent use) (%) 5.7 4.2 7.3 3.7 7.5
Last Month Prevalence (Current use) (%) 4.0 3.0 4.9 2.1 5.6
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
Table 2: Ireland
Age of First Use of Sedatives, Tranquillisers or Anti-depressants (All Users)
 All    Young  Older 
 adults   adults  adults  
 15-64 Males Females 15-34 35-64
Total Weighted N (valid responses) (580) (222) (358) (184) (396)
Mean age of first use 32 32 32 21 37
Median of age of first use1 30 28 30 20 35
1. Median is used as a measure of central tendency to avoid extreme values skewing results.
All figures are based on weighted data. 
All figures are based on valid responses.
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Table 3: Ireland
Frequency of Use* of Sedatives, Tranquillisers  
or Anti-depressants (Current Users) (%)
 All    Young Older 
 adults   adults adults 
 15-64 Males Females 15-34 35-64
Total Weighted N  
(valid responses) (194) (75) (119) (48) (146)
20 days or more 81.1 80.9 81.3 67.5 85.7
10-19 days 2.7 2.6 2.7 3.0 2.6
4-9 days 4.1 2.5 5.0 2.4 4.6
1-3 days 9.5 12.7 7.5 22.7 5.1
Don’t know 2.6 1.3 3.5 4.4 2.0
* EMCDDA ‘Handbook for Surveys on Drug Use Among the General 
Population’ (Aug. 2002) defines frequency of drug use as:
20 days or more = daily or almost daily. 
10-19 days = several times a week. 
4-9 days = at least once a week. 
1-3 days = less than once a week.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
Table 4: Ireland
Method of Taking Sedatives, Tranquillisers  
or Anti-depressants (Current Users) (%)
 All    Young Older 
 adults   adults adults 
 15-64 Males Females 15-34 35-64
Total Weighted N  
(valid responses) (194) (75) (119) (48) (146)
Tablets 97.9 97.1 98.5 96.2 98.5
Injection/Needle 2.2 4.6 0.6 1.4 2.4
Other 1.2 1.5 0.9 2.3 0.8
Don’t Know 0.0 0.0 0.0 0.0 0.0
This was a multi-choice question, therefore percentages may  
not total 100%.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
Table 5: Ireland
How Sedatives, Tranquillisers or Anti-depressants  
were Obtained (Current Users) (%)
 All    Young Older 
 adults   adults adults 
 15-64 Males Females 15-34 35-64
Total Weighted N  
(valid responses) (192) (74) (118) (48) (144)
I got them  
on prescription 94.7 94.5 94.8 84.2 98.2
I got them  
from someone  
else I know 2.4 1.9 2.8 8.3 0.5
I bought them  
without a  
prescription  
in a chemist 1.1 0.0 1.9 2.9 0.6
None of the above 1.7 3.5 0.6 4.7 0.7
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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Table 6: Ireland
Sedatives, Tranquillisers or Anti-depressants Prevalence  
by Gender (%)
Lifetime* Male Female Total
Total Weighted N  
(valid responses) (2470) (2448) (4918)
No 90.7 85.0 87.9
Yes 9.3 15.0 12.1
Last Year* Male Female Total
Total Weighted N  
(valid responses) (2470) (2448) (4918)
No 95.8 92.7 94.3
Yes 4.2 7.3 5.7
Last Month* Male Female Total
Total Weighted N  
(valid responses) (2470) (2448) (4918)
No 97.0 95.1 96.0
Yes 3.0 4.9 4.0
* p <= 0.05.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
Table 7: Ireland
Sedatives, Tranquillisers or Anti-depressants Prevalence  
by Age Group (%)
 Young Older 
 adults  adults 
Lifetime* 15-34 35-64 Total
Total Weighted N  
(valid responses) (2333) (2584) (4917)
No 91.8 84.3 87.9
Yes 8.2 15.7 12.1
 Young Older 
 adults  adults 
Last Year* 15-34 35-64 Total
Total Weighted N  
(valid responses) (2333) (2584) (4917)
No 96.3 92.5 94.3
Yes 3.7 7.5 5.7
 Young Older 
 adults  adults 
Last Month* 15-34 35-64 Total
Total Weighted N  
(valid responses) (2333) (2584) (4917)
No 97.9 94.4 96.0
Yes 2.1 5.6 4.0
* p <= 0.05.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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Table 8: Ireland
Sedatives, Tranquillisers or Anti-depressants Prevalence by Socio-Economic Group (%)
Lifetime* A B C1 C2 D E Total
Total Weighted N (valid responses) (174) (767) (1573) (1147) (842) (409) (4912)
No 87.3 88.0 89.2 90.4 88.5 74.8 87.9
Yes 12.7 12.0 10.8 9.6 11.5 25.2 12.1
Last Year* A B C1 C2 D E Total
Total Weighted N (valid responses) (174) (767) (1573) (1147) (842) (409) (4912)
No 93.1 95.4 94.7 96.5 94.8 84.1 94.3
Yes 6.9 4.6 5.3 3.5 5.2 15.9 5.7
Last Month* A B C1 C2 D E Total
Total Weighted N (valid responses) (174) (767) (1573) (1147) (842) (409) (4912)
No 94.8 96.9 96.8 97.6 96.3 86.8 96.0
Yes 5.2 3.1 3.2 2.4 3.7 13.2 4.0
* p <= 0.05.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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Table 9: Ireland
Sedatives, Tranquillisers or Anti-depressants Prevalence by Work Status (%)
 In paid  Not in  
Lifetime* work paid work Student Other Total
Total Weighted N (valid responses) (3139) (1090) (657) (24) (4910)
No 90.1 77.5 94.7 75.0 87.9
Yes 9.9 22.5 5.3 25.0 12.1
 In paid  Not in  
Last Year* work paid work Student Other Total
Total Weighted N (valid responses) (3139) (1090) (657) (24) (4910)
No 96.0 87.6 97.3 83.3 94.3
Yes 4.0 12.4 2.7 16.7 5.7
 In paid  Not in  
Last Month* work paid work Student Other Total
Total Weighted N (valid responses) (3139) (1090) (657) (24) (4910)
No 97.6 90.3 98.2 87.5 96.0
Yes 2.4 9.7 1.8 12.5 4.0
* p <= 0.05.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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Table 10: Ireland
Sedatives, Tranquillisers or Anti-depressants Prevalence by Housing Tenure (%)
 Owned in  Rented from  Rented from  
Lifetime* part or full private landlord LA/HA Other Total
Total Weighted N (valid responses) (3719) (607) (453) (139) (4918)
No 88.4 87.6 81.9 95.7 87.9
Yes 11.6 12.4 18.1 4.3 12.1
 Owned in  Rented from  Rented from  
Last Year* part or full private landlord LA/HA Other Total
Total Weighted N (valid responses) (3719) (607) (453) (139) (4918)
No 94.4 95.6 90.3 99.3 94.3
Yes 5.6 4.4 9.7 0.7 5.7
 Owned in  Rented from  Rented from  
Last Month* part or full private landlord LA/HA Other Total
Total Weighted N (valid responses) (3719) (607) (453) (139) (4918)
No 96.1 97.7 91.9 99.3 96.0
Yes 3.9 2.3 8.1 0.7 4.0
* p <= 0.05. 
LA/HA = Local Authority or Housing Association.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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Table 11: Ireland
Sedatives, Tranquillisers or Anti-depressants Prevalence by Age Education Ceased (%)
 15 years   20 years  
Lifetime & under 16-19 & over Total
Total Weighted N (valid responses) (738) (2051) (1070) (3859)
No 84.3 87.7 87.2 86.9
Yes 15.7 12.3 12.8 13.1
 15 years   20 years  
Last Year* & under 16-19 & over Total
Total Weighted N (valid responses) (738) (2051) (1070) (3859)
No 91.2 94.6 94.5 93.9
Yes 8.8 5.4 5.5 6.1
 15 years   20 years  
Last Month & under 16-19 & over Total
Total Weighted N (valid responses) (738) (2051) (1070) (3859)
No 92.4 96.4 96.2 95.6
Yes 7.6 3.6 3.8 4.4
* p <= 0.05.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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Table 12: Ireland
Sedatives, Tranquillisers or Anti-depressants Prevalence by Highest Education Level Attained (%)
  Lower  Upper  
Lifetime* Primary second level second level Third level Total
Total Weighted N (valid responses) (456) (1551) (1361) (1545) (4913)
No 84.2 88.3 89.1 87.3 87.8
Yes 15.8 11.7 10.9 12.7 12.2
  Lower  Upper  
Last Year* Primary second level second level Third level Total
Total Weighted N (valid responses) (456) (1551) (1361) (1545) (4913)
No 90.1 94.7 94.8 94.6 94.3
Yes 9.9 5.3 5.2 5.4 5.7
  Lower  Upper  
Last Month* Primary second level second level Third level Total
Total Weighted N (valid responses) (456) (1551) (1361) (1545) (4913)
No 90.8 96.5 96.5 96.8 96.0
Yes 9.2 3.5 3.5 3.2 4.0
* p <= 0.05.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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Table 13: Ireland
Sedatives, Tranquillisers or Anti-depressants Prevalence by Marital Status (%)
Lifetime* Single Married Co-habiting Separated Divorced Widowed Total
Total Weighted N (valid responses) (2065) (2281) (241) (178) (45) (105) (4915)
No 89.8 88.6 87.1 73.6 57.8 72.4 87.9
Yes 10.2 11.4 12.9 26.4 42.2 27.6 12.1
Last Year* Single Married Co-habiting Separated Divorced Widowed Total
Total Weighted N (valid responses) (2065) (2281) (241) (178) (45) (105) (4915)
No 94.7 94.6 96.3 87.6 86.7 87.5 94.3
Yes 5.3 5.4 3.7 12.4 13.3 12.5 5.7
Last Month* Single Married Co-habiting Separated Divorced Widowed Total
Total Weighted N (valid responses) (2065) (2281) (241) (178) (45) (105) (4915)
No 96.5 96.2 97.9 89.3 93.5 90.4 96.0
Yes 3.5 3.8 2.1 10.7 6.5 9.6 4.0
* p <= 0.05.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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Table 14: Northern Ireland
Sedatives, Tranquillisers or Anti-depressants – Prevalence Rates (%)
 All    Young Older 
 adults    adults adults 
 15-64 Males Females 15-34 35-64
Total Weighted N (valid responses) (3516) (1739) (1777) (1548) (1966)
Lifetime Prevalence (%) 22.1 15.5 28.5 16.2 26.7
Last Year Prevalence (Recent use) (%) 12.6 8.7 16.5 8.6 15.8
Last Month Prevalence (Current use) (%) 9.8 7.0 12.5 5.4 13.2
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
Table 15: Northern Ireland
Age of First Use of Sedatives, Tranquillisers or Anti-depressants (All Users)
 All    Young Older 
 adults    adults adults 
 15-64 Males Females 15-34 35-64
Total Weighted N (valid responses) (762) (265) (497) (245) (517)
Mean age of first use 33 33 32 23 37
Median of age of first use1 30 32 30 22 37
1. Median is used as a measure of central tendency to avoid extreme values skewing results.
All figures are based on weighted data. 
All figures are based on valid responses.
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Table 16: Northern Ireland
Frequency of Use* of Sedatives, Tranquillisers or Anti-depressants (Current Users) (%)
 All    Young Older 
 adults    adults adults 
Frequency of use (%)* 15-64 Males Females 15-34 35-64
Total Weighted N (valid responses) (343) (121) (222) (83) (260)
20 days or more 83.8 82.1 84.7 84.7 83.5
10-19 days 4.2 4.5 4.1 3.7 4.4
4-9 days 5.2 4.7 5.5 4.7 5.4
1-3 days 6.3 8.1 5.4 6.8 6.2
Don’t know 0.4 0.6 0.3 0.0 0.6
* EMCDDA ‘Handbook for Surveys on Drug Use Among the General Population’ (Aug. 2002) defines frequency of drug use as:
20 days or more = daily or almost daily. 10-19 days = several times a week. 4-9 days = at least once a week. 1-3 days = less than once a week.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
Table 17: Northern Ireland
Method of Taking Sedatives, Tranquillisers or Anti-depressants (Current Users) (%)
 All    Young Older 
 adults    adults  adults  
 15-64 Males Females 15-34 35-64
Total Weighted N (valid responses) (343) (121) (222) (83) (260)
Tablets 98.7 99.1 98.5 96.0 99.6
Injection/Needle 2.3 2.6 2.2 5.3 1.4
Other 0.5 0.0 0.8 0.0 0.7
Don’t Know 0.0 0.0 0.0 0.0 0.0
This was a multi-choice question, therefore percentages may not total 100%.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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Table 18: Northern Ireland
How Sedatives, Tranquillisers or Anti-depressants were Obtained (Current Users) (%)
 All    Young Older 
 adults    adults  adults  
 15-64 Males Females 15-34 35-64
Total Weighted N (valid responses) (342) (120) (222) (83) (259)
I got them on prescription 97.6 97.5 97.7 97.2 97.7
I got them from someone else I know 0.3 1.0 0.0 0.0 0.4
I bought them without a prescription in a chemist 1.1 1.6 0.8 0.0 1.5
None of the above 0.9 0.0 1.5 2.8 0.3
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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Table 19: Northern Ireland
Sedatives, Tranquillisers or Anti-depressants Prevalence  
by Gender (%)
Lifetime* Male Female Total
Total Weighted N  
(valid responses) (1739) (1777) (3516)
No 84.5 71.5 77.9
Yes 15.5 28.5 22.1
Last Year* Male Female Total
Total Weighted N  
(valid responses) (1739) (1777) (3516)
No 91.3 83.5 87.4
Yes 8.7 16.5 12.6
Last Month* Male Female Total
Total Weighted N  
(valid responses) (1739) (1777) (3516)
No 93.0 87.5 90.2
Yes 7.0 12.5 9.8
* p <= 0.05.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
Table 20: Northern Ireland
Sedatives, Tranquillisers or Anti-depressants Prevalence  
by Age Group (%)
 Young Older 
 adults adults 
Lifetime* 15-34 35-64 Total
Total Weighted N  
(valid responses) (1548) (1967) (3515)
No 83.9 73.3 77.9
Yes 16.1 26.7 22.1
 Young Older 
 adults adults 
Last Year* 15-34 35-64 Total
Total Weighted N  
(valid responses) (1548) (1967) (3515)
No 91.4 84.2 87.4
Yes 8.6 15.8 12.6
 Young Older 
 adults adults 
Last Month* 15-34 35-64 Total
Total Weighted N  
(valid responses) (1548) (1967) (3515)
No 94.6 86.8 90.2
Yes 5.4 13.2 9.8
* p <= 0.05.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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Table 21: Northern Ireland
Sedatives, Tranquillisers or Anti-depressants Prevalence by Socio-Economic Group (%)
Lifetime* A B C1 C2 D E Total
Total Weighted N (valid responses) (76) (473) (977) (597) (619) (774) (3516)
No 84.0 86.3 81.1 84.1 79.4 62.3 77.9
Yes 16.0 13.7 18.9 15.9 20.6 37.7 22.1
Last Year* A B C1 C2 D E Total
Total Weighted N (valid responses) (76) (473) (977) (597) (619) (774) (3516)
No 93.4 93.9 91.3 93.0 88.5 72.5 87.3
Yes 6.6 6.1 8.7 7.0 11.5 27.5 12.7
Last Month* A B C1 C2 D E Total
Total Weighted N (valid responses) (76) (473) (977) (597) (619) (774) (3516)
No 93.4 96.2 93.4 95.3 91.4 77.3 90.2
Yes 6.6 3.8 6.6 4.7 8.6 22.7 9.8
* p =< 0.05.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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Table 22: Northern Ireland
Sedatives, Tranquillisers or Anti-depressants Prevalence by Work Status (%)
 In paid  Not in  
Lifetime* work paid work Student Other Total
Total Weighted N (valid responses) (2040) (1130) (333) (13) (3516)
No 83.4 62.8 95.8 75.0 77.9
Yes 16.6 37.2 4.2 25.0 22.1
 In paid  Not in  
Last Year* work paid work Student Other Total
Total Weighted N (valid responses) (2040) (1130) (333) (13) (3516)
No 92.1 75.5 98.5 92.3 87.4
Yes 7.9 24.5 1.5 7.7 12.6
 In paid  Not in  
Last Month* work paid work Student Other Total
Total Weighted N (valid responses) (2040) (1130) (333) (13) (3516)
No 94.6 79.5 99.4 100.0 90.2
Yes 5.4 20.5 0.6 0.0 9.8
* p =< 0.05.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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Table 23: Northern Ireland
Sedatives, Tranquillisers or Anti-depressants Prevalence by Housing Tenure (%)
  Rented from  
Lifetime* Owned private landlord Other rented Rent free Other answer Total
Total Weighted N (valid responses) (2448) (275) (752) (19) (6) (3500)
No 81.7 72.3 66.7 89.5 100.0 77.8
Yes 18.3 27.7 33.3 10.5 0.0 22.2
  Rented from  
Last Year* Owned private landlord Other rented Rent free Other answer Total
Total Weighted N (valid responses) (2448) (275) (752) (19) (6) (3500)
No 90.9 83.3 76.8 89.5 100.0 87.3
Yes 9.1 16.7 23.2 10.5 0.0 12.7
  Rented from  
Last Month* Owned private landlord Other rented Rent free Other answer Total
Total Weighted N (valid responses) (2448) (275) (752) (19) (6) (3500)
No 93.3 86.5 81.3 89.5 100.0 90.2
Yes 6.7 13.5 18.7 10.5 0.0 9.8
* p =< 0.05.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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Table 24: Northern Ireland
Sedatives, Tranquillisers or Anti-depressants Prevalence by Educational Qualifications (%)
Lifetime* Qualifications No Qualifications Total
Total Weighted N (valid responses) (2367) (1145) (3512)
No 79.9 74.0 78.0
Yes 20.1 26.0 22.0
Last Year* Qualifications No Qualifications Total
Total Weighted N (valid responses) (2367) (1145) (3512)
No 89.4 83.2 87.4
Yes 10.6 16.8 12.6
Last Month* Qualifications No Qualifications Total
Total Weighted N (valid responses) (2367) (1145) (3512)
No 92.5 85.4 90.2
Yes 7.5 14.6 9.8
* p =< 0.05.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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Table 25: Northern Ireland
Sedatives, Tranquillisers or Anti-depressants Prevalence by Marital Status (%)
Lifetime* Single Married Co-habiting Separated Divorced Widowed Total
Total Weighted N (valid responses) (1344) (1490) (178) (213) (202) (85) (3512)
No 84.4 78.8 77.1 60.1 57.9 55.3 77.9
Yes 15.6 21.2 22.9 39.9 42.1 44.7 22.1
Last Year* Single Married Co-habiting Separated Divorced Widowed Total
Total Weighted N (valid responses) (1344) (1490) (178) (213) (202) (85) (3512)
No 90.8 88.7 86.0 74.2 74.3 77.4 87.4
Yes 9.2 11.3 14.0 25.8 25.7 22.6 12.6
Last Month* Single Married Co-habiting Separated Divorced Widowed Total
Total Weighted N (valid responses) (1344) (1490) (178) (213) (202) (85) (3512)
No 93.1 91.1 92.1 81.2 78.6 77.6 90.3
Yes 6.9 8.9 7.9 18.8 21.4 22.4 9.7
* p <= 0.05.
All figures are based on weighted data. 
All figures are rounded to the nearest decimal place. 
All figures are based on valid responses.
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